- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.06. | Remix Therapeutics to go public in reverse merger with once high-flying Passage Bio | ||
| 25.06. | Antares gets $105M from Novartis for new cancer drugs | ||
| 24.06. | Investors pour $115M into RQ Bio in search of a preventive flu drug | ||
| 24.06. | To Wall Street, psychedelics biotechs are more teammates than rivals | ||
| 24.06. | Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor | ||
| 24.06. | Ollin refuels with $330M to back pivotal tests of Vabysmo challenger | ||
| 23.06. | Pfizer drug acquired in Seagen deal disappoints in lung cancer study | ||
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | ||
| 23.06. | HHS, responding to China's rise, moves to fast-track early drug research | ||
| 23.06. | 'The window's open': At BIO, investors take stock of a growing class of biotech IPOs | ||
| 23.06. | Hospitals irate after Eli Lilly follows through on 340B ultimatum | ||
| 22.06. | Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection | ||
| 22.06. | Sanofi swaps R&D leaders; Merck's Prometheus deal pays dividends | ||
| 22.06. | AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs | ||
| 22.06. | Bionyra brings in $165M for next-generation immune drugs | ||
| 22.06. | From episodes to a lifetime: How AI can enable women's health brands to build a partnership that lasts | ||
| 22.06. | The first 14 days: How specialty programs set patients up for success | ||
| 18.06. | Moderna flu vaccine wins unanimous support from FDA panel | ||
| 18.06. | cAMPfield lands $180M to build gut disease drug | ||
| 18.06. | Biogen adds more immune drugs in $1B buyout of secretive startup Raythera | ||
| 18.06. | Pfizer CFO to step down; Denali sells a regulatory fast-pass | ||
| 17.06. | UniQure to file gene therapy for approval, reflecting major shifts at FDA | ||
| 17.06. | Jazz zeroes in on next-gen T cell engagers with AbCellera deal | ||
| 17.06. | A new Westlake-backed biotech takes aim at migraines | ||
| 16.06. | Lilly buys non-opioid pain drugmaker 4E |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.